Search

BARCELONA—The finding from the phase-III ARCON trial presented at the 3rd ESTRO Forum that: Accelerated radiotherapy with carbogen and nicotinamide (ARCON) significantly improved outcomes for patients

BARCELONA—Accelerated radiotherapy with carbogen and nicotinamide (ARCON) significantly improved regional control while maintaining excellent speech and swallowing for a majority of patients with adva

BARCELONA—There was no improvement in biochemical progression free survival among patients who had their high-risk localized prostate cancers treated with elective pelvic nodal irradiation compared wi

BARCELONA – For patients with locally advanced cervical cancer, combining intracavitary and interstitial (IC/IS) brachytherapy techniques should be the benchmark treatment. That’s accordin

BARCELONA – The 3rd European Society for Radiotherapy & Oncology Forum — ESTRO — was held this year in Barcelona featuring all aspects of the radiation oncology field. Oncology Times report

BARCELONA—Men with intermediate- or high-risk prostate cancer who were treated with low dose rate prostate brachytherapy (LDR-PB) were twice as often cancer-free at five years compared to those given

BARCELONA – Brachytherapy with or without external beam radiation improved survival in patients with early-stage, inoperable endometrial cancer. That’s according to findings of a populatio

GENEVA— The IGNITE study from Chinese researchers has demonstrated how plasma—and not just tissue samples—could be used to distinguish patients with non-small cell lung cancer who could benefit from E

GENEVA—An alternative way of testing for mutated EGFR in patients with advanced non-small cell lung cancer was validated in research presented at the European Lung Cancer Conference by Martin Reck MD

GENEVA— Almost one in four patients with advanced lung cancer in Europe, Asia and the US are not receiving EGFR test results before being started on treatment—according to a report presented at the Eu

GENEVA—Findings from the retrospective EURAF study suggest that many patients with BRAF-mutant lung cancers could benefit from treatment with BRAF inhibitors, although specific studies need to be done

GENEVA—Two thirds of patients with advanced non-small cell lung cancer that had failed first line anti-EGFR therapy responded to a new drug: AZD9291 according to findings discussed at the European Lun